Kalorama Presents at BIOMedevice San Jose
The point of care diagnostic testing market is over $22 billion, about 2/3rds of that is self-care and physician office based testing.
Point of care testing offers significant benefits in time-to-results, time-to-treatment, diagnostic relevance to providers and even patient confidence. They tend to cost more than lab-based tests, but in an overall context of care cost, they can prove to contribute to overall savings and outcomes improvement.
Kalorama Information presented at the BioMedevice San Jose – https://biomedevicesanjose.com/ The Presentation will be on “Point of Care: Fast Growth, New Products, Disruptive Trends. ”
Some key points
- Point of Care Grows Faster
- Point of Care Needs to Prove Benefits.
- As more than a fourth of the IVD market, POC has withstood cost challenges
- Cardiac, HbA1c, Tumor Markers, FOB among fast-growing segments
For a copy of Kalorama Publisher Bruce Carlson’s presentation at the event, please email [email protected]
For More Information on the Point of Care Market, See Kalorama Information’s report:
The Worldwide Market for Point-of-Care (POC) Testing (Infectious Disease Testing, POC Cancer Tests, Rapid Coagulation, Urine Testing, Lipid Tests, Pregnancy Testing, Glucose Testing and Other POC)
